Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1995 Feb;63(2):707–709. doi: 10.1128/iai.63.2.707-709.1995

Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.

R Lagos 1, A Avendaño 1, V Prado 1, I Horwitz 1, S Wasserman 1, G Losonsky 1, S Cryz Jr 1, J B Kaper 1, M M Levine 1
PMCID: PMC173056  PMID: 7822046

Abstract

Persons of blood group O are at increased risk of developing cholera gravis. In a randomized, placebo-controlled, double-blind safety-immunogenicity trial of live oral cholera vaccine CVD 103-HgR in 5- to 9-year-old Chilean children, vibriocidal antibody seroconversion (74% overall) did not differ by blood group. However, the reciprocal geometric mean titer (GMT) in blood group O vaccines (GMT = 486) was higher than that in non-O vaccines (GMT = 179) (P < 0.02).

Full Text

The Full Text of this article is available as a PDF (180.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barua D., Paguio A. S. ABO blood groups and cholera. Ann Hum Biol. 1977 Sep;4(5):489–492. doi: 10.1080/03014467700002481. [DOI] [PubMed] [Google Scholar]
  2. Benenson A. S., Saad A., Mosley W. H. Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique. Bull World Health Organ. 1968;38(2):277–285. [PMC free article] [PubMed] [Google Scholar]
  3. Borén T., Falk P., Roth K. A., Larson G., Normark S. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science. 1993 Dec 17;262(5141):1892–1895. doi: 10.1126/science.8018146. [DOI] [PubMed] [Google Scholar]
  4. Clausen H., Hakomori S. ABH and related histo-blood group antigens; immunochemical differences in carrier isotypes and their distribution. Vox Sang. 1989;56(1):1–20. doi: 10.1111/j.1423-0410.1989.tb03040.x. [DOI] [PubMed] [Google Scholar]
  5. Clemens J. D., Sack D. A., Harris J. R., Chakraborty J., Khan M. R., Huda S., Ahmed F., Gomes J., Rao M. R., Svennerholm A. M. ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. J Infect Dis. 1989 Apr;159(4):770–773. doi: 10.1093/infdis/159.4.770. [DOI] [PubMed] [Google Scholar]
  6. Clemens J. D., Stanton B. F., Chakraborty J., Sack D. A., Khan M. R., Huda S., Ahmed F., Harris J. R., Yunus M., Khan M. U. B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. J Infect Dis. 1987 Jan;155(1):79–85. doi: 10.1093/infdis/155.1.79. [DOI] [PubMed] [Google Scholar]
  7. Clemens J. D., van Loon F., Sack D. A., Rao M. R., Ahmed F., ChakrabortY J., Kay B. A., Khan M. R., Yunus M. D., Harris J. R. Biotype as determinant of natural immunising effect of cholera. Lancet. 1991 Apr 13;337(8746):883–884. doi: 10.1016/0140-6736(91)90207-6. [DOI] [PubMed] [Google Scholar]
  8. Finne J., Breimer M. E., Hansson G. C., Karlsson K. A., Leffler H., Vliegenthart J. F., van Halbeek H. Novel polyfucosylated N-linked glycopeptides with blood group A, H, X, and Y determinants from human small intestinal epithelial cells. J Biol Chem. 1989 Apr 5;264(10):5720–5735. [PubMed] [Google Scholar]
  9. Glass R. I., Becker S., Huq M. I., Stoll B. J., Khan M. U., Merson M. H., Lee J. V., Black R. E. Endemic cholera in rural Bangladesh, 1966-1980. Am J Epidemiol. 1982 Dec;116(6):959–970. doi: 10.1093/oxfordjournals.aje.a113498. [DOI] [PubMed] [Google Scholar]
  10. Glass R. I., Holmgren J., Haley C. E., Khan M. R., Svennerholm A. M., Stoll B. J., Belayet Hossain K. M., Black R. E., Yunus M., Barua D. Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am J Epidemiol. 1985 Jun;121(6):791–796. doi: 10.1093/oxfordjournals.aje.a114050. [DOI] [PubMed] [Google Scholar]
  11. Gotuzzo E., Butron B., Seas C., Penny M., Ruiz R., Losonsky G., Lanata C. F., Wasserman S. S., Salazar E., Kaper J. B. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun. 1993 Sep;61(9):3994–3997. doi: 10.1128/iai.61.9.3994-3997.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hanne L. F., Finkelstein R. A. Characterization and distribution of the hemagglutinins produced by Vibrio cholerae. Infect Immun. 1982 Apr;36(1):209–214. doi: 10.1128/iai.36.1.209-214.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Herrington D. A., Hall R. H., Losonsky G., Mekalanos J. J., Taylor R. K., Levine M. M. Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med. 1988 Oct 1;168(4):1487–1492. doi: 10.1084/jem.168.4.1487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jonson G., Sanchez J., Svennerholm A. M. Expression and detection of different biotype-associated cell-bound haemagglutinins of Vibrio cholerae O1. J Gen Microbiol. 1989 Jan;135(1):111–120. doi: 10.1099/00221287-135-1-111. [DOI] [PubMed] [Google Scholar]
  15. Kaper J. B., Levine M. M. Recombinant attenuated Vibrio cholerae strains used as live oral vaccines. Res Microbiol. 1990 Sep-Oct;141(7-8):901–906. doi: 10.1016/0923-2508(90)90128-d. [DOI] [PubMed] [Google Scholar]
  16. Kotloff K. L., Wasserman S. S., O'Donnell S., Losonsky G. A., Cryz S. J., Levine M. M. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun. 1992 Oct;60(10):4430–4432. doi: 10.1128/iai.60.10.4430-4432.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lagos R., Avendaño A., Horwitz I., Prado V., Ferreccio C., Sotomayor V., Losonsky G., Wasserman S. S., Cryz S., Kaper J. B. Tolerancia e inmunogenicidad de una dosis oral de la cepa de Vibrio cholerae 01, viva-atenuada, CVD 103--HgR: estudio doble ciego en adultos chilenos. Rev Med Chil. 1993 Aug;121(8):857–863. [PubMed] [Google Scholar]
  18. Levine M. M., Black R. E., Clements M. L., Cisneros L., Nalin D. R., Young C. R. Duration of infection-derived immunity to cholera. J Infect Dis. 1981 Jun;143(6):818–820. doi: 10.1093/infdis/143.6.818. [DOI] [PubMed] [Google Scholar]
  19. Levine M. M., Kaper J. B., Herrington D., Ketley J., Losonsky G., Tacket C. O., Tall B., Cryz S. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet. 1988 Aug 27;2(8609):467–470. doi: 10.1016/s0140-6736(88)90120-1. [DOI] [PubMed] [Google Scholar]
  20. Levine M. M., Kaper J. B. Live oral vaccines against cholera: an update. Vaccine. 1993;11(2):207–212. doi: 10.1016/0264-410x(93)90019-t. [DOI] [PubMed] [Google Scholar]
  21. Levine M. M., Nalin D. R., Rennels M. B., Hornick R. B., Sotman S., Van Blerk G., Hughes T. P., O'Donnell S., Barua D. Genetic susceptibility to cholera. Ann Hum Biol. 1979 Jul-Aug;6(4):369–374. doi: 10.1080/03014467900003751. [DOI] [PubMed] [Google Scholar]
  22. Levine M. M., Young C. R., Black R. E., Takeda Y., Finkelstein R. A. Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology. J Clin Microbiol. 1985 Feb;21(2):174–179. doi: 10.1128/jcm.21.2.174-179.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pineau J. C., Vol S., Tichet J. Modélisation et standardisation de la corpulence chez les Français âgés de 18 à 59 ans. C R Acad Sci III. 1995 Jun;318(6):709–714. [PubMed] [Google Scholar]
  24. Ries A. A., Vugia D. J., Beingolea L., Palacios A. M., Vasquez E., Wells J. G., Garcia Baca N., Swerdlow D. L., Pollack M., Bean N. H. Cholera in Piura, Peru: a modern urban epidemic. J Infect Dis. 1992 Dec;166(6):1429–1433. doi: 10.1093/infdis/166.6.1429. [DOI] [PubMed] [Google Scholar]
  25. Sack D. A., Clemens J. D., Huda S., Harris J. R., Khan M. R., Chakraborty J., Yunus M., Gomes J., Siddique O., Ahmed F. Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh. J Infect Dis. 1991 Aug;164(2):407–411. doi: 10.1093/infdis/164.2.407. [DOI] [PubMed] [Google Scholar]
  26. Simanjuntak C. H., O'Hanley P., Punjabi N. H., Noriega F., Pazzaglia G., Dykstra P., Kay B., Suharyono, Budiarso A., Rifai A. R. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. J Infect Dis. 1993 Nov;168(5):1169–1176. doi: 10.1093/infdis/168.5.1169. [DOI] [PubMed] [Google Scholar]
  27. Su-Arehawaratana P., Singharaj P., Taylor D. N., Hoge C., Trofa A., Kuvanont K., Migasena S., Pitisuttitham P., Lim Y. L., Losonsky G. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis. 1992 Jun;165(6):1042–1048. doi: 10.1093/infdis/165.6.1042. [DOI] [PubMed] [Google Scholar]
  28. Suharyono, Simanjuntak C., Witham N., Punjabi N., Heppner D. G., Losonsky G., Totosudirjo H., Rifai A. R., Clemens J., Lim Y. L. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet. 1992 Sep 19;340(8821):689–694. doi: 10.1016/0140-6736(92)92231-4. [DOI] [PubMed] [Google Scholar]
  29. Taylor R. K., Miller V. L., Furlong D. B., Mekalanos J. J. Use of phoA gene fusions to identify a pilus colonization factor coordinately regulated with cholera toxin. Proc Natl Acad Sci U S A. 1987 May;84(9):2833–2837. doi: 10.1073/pnas.84.9.2833. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES